The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. - Wikidata - awgldk - TriplyDB

The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

http://www.wikidata.org/entity/Q30546337

about

Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy Spinal muscular atrophy: development and implementation of potential treatments Collaboration for rare disease drug discovery research Loss of the scavenger mRNA decapping enzyme DCPS causes syndromic intellectual disability with neuromuscular defects Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy Quality control of assembly-defective U1 snRNAs by decapping and 5'-to-3' exonucleolytic digestion.Assays for the identification and prioritization of drug candidates for spinal muscular atrophy Transcriptome profiling of spinal muscular atrophy motor neurons derived from mouse embryonic stem cells GEMINs: potential therapeutic targets for spinal muscular atrophy?Presynaptic localization of Smn and hnRNP R in axon terminals of embryonic and postnatal mouse motoneurons Spinal Muscular Atrophy Therapeutics: Where do we Stand?Elimination of cap structures generated by mRNA decay involves the new scavenger mRNA decapping enzyme Aph1/FHIT together with DcpS.A cell system for phenotypic screening of modifiers of SMN2 gene expression and function.Spinal muscular atrophy: from tissue specificity to therapeutic strategies Advances in therapeutic development for spinal muscular atrophy.ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy.A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS.Disease mechanisms and therapeutic approaches in spinal muscular atrophy.DcpS is a transcript-specific modulator of RNA in mammalian cells.The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.A fluorescent HTS assay for phosphohydrolases based on nucleoside 5'-fluorophosphates: its application in screening for inhibitors of mRNA decapping scavenger and PDE-I.Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.Genetic inhibition of JNK3 ameliorates spinal muscular atrophy.Spinal muscular atrophy: an update on therapeutic progress Developing therapies for spinal muscular atrophy.Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy.The human decapping scavenger enzyme DcpS modulates microRNA turnover.An excess of catalytically required motions inhibits the scavenger decapping enzyme.The effects of C5-substituted 2,4-diaminoquinazolines on selected transcript expression in spinal muscular atrophy cells In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.Cellular thermal shift and clickable chemical probe assays for the determination of drug-target engagement in live cells

P2860

Q26752798-D8D2CFF9-D41E-4C6E-A0D9-651953B9147D Q26861377-C9261ABD-24ED-476A-A2AB-F3926D22A787 Q28650560-13578132-C95E-4867-A151-5208ED8BB237 Q30649520-16A958CC-9790-4A0D-8A2A-E36D0378995F Q30743508-2B0283AD-306B-444A-B732-BEC35258185F Q33645966-6C2C5553-0ECD-404C-AED5-1C0BE39BBC6E Q34001036-ACF91DC2-5A3B-4F62-8E4C-A05418724523 Q34060813-7066DDBE-F3D8-476E-9681-FE9B8D78C8D9 Q34082155-71C2C9B8-D36F-4CC1-9B58-A31949067BB7 Q34142599-03A971D9-5E1B-4A5F-840E-BC12A2A0C55E Q34342044-9929346B-89BF-4098-AE85-FF1748DAE0DA Q34388403-6AB39C9D-59E3-435E-88D0-F965A19372A9 Q34460251-43AB1C4D-600C-497B-B3CF-D3D616247EA4 Q34882994-70099854-4E33-47BE-8975-C080412C4208 Q34964785-51A325A8-0F6E-446B-91D9-3A69BD97CCEE Q35029616-822832F6-5851-4864-8184-3FA586B6AA8E Q35167319-1322584F-7BBD-4E27-882D-0FF5EF1BB8BE Q35530447-8169B280-9051-431F-B654-59FE57D44152 Q35626397-DFA3EB9F-E8B4-4BD8-8F23-35E291DD104B Q35707832-0BE5C2E7-CC71-45C7-BCDA-C2B8A7B07CF2 Q35773274-54D374EE-A51D-4FAB-8109-728324989D46 Q35967715-FA40E823-6150-4B6D-B547-4D9CBD78A102 Q35975257-4A9B2793-A95B-4802-A2D3-73D71FA3D6AA Q36095048-5181D118-DB0C-4083-8311-5D69E25F9F45 Q36238337-4792A5EA-F3CE-4BF8-95F2-D0D43994ED5C Q36302096-C117D962-30DE-48A6-8801-9C75E0A54ACC Q37302832-3F9E6964-8417-4A12-9F19-32972DC5C2C8 Q38546908-364819CC-3A85-47B6-9682-9A5108203FEB Q38704353-50E0FBA5-F1CB-44B8-AFAD-B96D008CE902 Q38843108-69160789-314C-485D-BAB0-59A33E452921 Q40302008-A14E032A-53C5-4042-A9BB-370E654B3210 Q40641429-92D7FA71-D7C9-4509-BDFE-8E36971CE80D Q41000953-4722C26B-218C-4F5E-8ED6-1872FDAC3085 Q42273778-E90427A4-DCB1-4157-9FF6-4854558260B9 Q52686206-A74B4AA3-3F58-4356-A7B8-BEE9A9ACCE06 Q58293026-92F77E91-58FA-4EDF-9AFD-E67958AAAC1E

P2860

The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

http://www.wikidata.org/entity/Q30546337

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@ast

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@en

type

label

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@ast

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@en

prefLabel

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@ast

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@en

P1433

Q30546337-69A0C8CE-E9D1-42ED-9305-8F6FBC5D01F9

P1476

Q30546337-23ABB71D-8653-47A9-8C55-3972D78FD3C7

P2093

Q30546337-0622526C-B68F-4F35-8810-E5784D0857D7

Q30546337-0ADCE598-A93F-4924-8A11-300A1C240EE3

Q30546337-16DEE5AE-0755-4943-95A2-8DAEA93FB97C

Q30546337-1F269BBB-032A-430B-A572-D48F9B0DDBAB

Q30546337-2E9D194D-3882-4C96-BFFC-4F01CEDCDE6D

Q30546337-3838BF08-8900-4293-A533-DDE8F6DACD65

Q30546337-4A3BE0F1-6353-4A72-A72F-F556CAEC0A29

Q30546337-52754179-1593-4DA8-BF98-4BF8C3EFC6DD

Q30546337-694061C3-90D0-4082-BF21-DD2041C85034

Q30546337-6E2BC0CC-BDB4-488E-9C3F-B096E42B8C29

P2860

Q30546337-000F7ACA-6372-4D82-BB65-189E00325438

Q30546337-0947CD00-6371-4BE2-98BB-BDA56D7F2E6A

Q30546337-0C28D51B-4CDD-4817-93C5-6F137392B3EC

Q30546337-1048678C-4ABF-49E9-A1BE-8AA839448E48

Q30546337-1E35421A-201C-483C-8BA9-301561361E4E

Q30546337-219473AA-DA79-496C-9BEA-E9685546FF1A

Q30546337-22C025CA-3744-4D54-A706-56B6166A97B7

Q30546337-2822C9A8-93AE-4D39-9E86-278A79401CCC

Q30546337-29A1203F-9569-4578-B8CA-47769709B7CB

Q30546337-3BFA6281-772A-42C1-A5D6-5FC4FD3E9290

P304

Q30546337-F7AB15B6-F6F3-4C75-BF3A-FB394945F1B4

P31

Q30546337-66BD1AD4-7ADD-40B6-8A5B-C956918726C4

P356

Q30546337-722CDA5B-7158-4E01-9B0F-7CB1113841F9

P433

Q30546337-936A9515-B612-403D-B4C6-64E75DD56D3A

P478

Q30546337-5FFCF167-9543-46E5-90C2-6DFF5878601C

P50

Q30546337-AF9BB385-2801-4D1A-AE51-6BDB73AAFFE1

P577

Q30546337-E719568E-DD01-4B91-A9FC-31F2DD6E8451

P5875

Q30546337-6ACBC293-48C3-4133-8F19-C2FE84F3E57E

P698

Q30546337-8BCDDC37-64C9-435E-B234-AE47968C656B

P932

Q30546337-19E57FE4-19E4-4AC0-A0FD-9297C2D22F15

P356

P1433

Human Molecular Genetics

P1476

The DcpS inhibitor RG3039 impr ...... ogies in two SMA mouse models.

@en

P2093

Bing Xia

http://www.w3.org/2001/XMLSchema#string

Carina Emery

http://www.w3.org/2001/XMLSchema#string

Christine J DiDonato

http://www.w3.org/2001/XMLSchema#string

Courtenay Barlow

http://www.w3.org/2001/XMLSchema#string

Heather L Plasterer

http://www.w3.org/2001/XMLSchema#string

Herminio Cardona

http://www.w3.org/2001/XMLSchema#string

James Rusche

http://www.w3.org/2001/XMLSchema#string

Jasbir Singh

http://www.w3.org/2001/XMLSchema#string

Jill Jarecki

http://www.w3.org/2001/XMLSchema#string

Madel Durens

http://www.w3.org/2001/XMLSchema#string

P2860

The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases

DcpS as a therapeutic target for spinal muscular atrophy.

DcpS scavenger decapping enzyme can modulate pre-mRNA splicing

A novel nuclear structure containing the survival of motor neurons protein

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.

Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery

Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

P304

4084-4101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDT258

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Heier

P577

2013-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237056367

http://www.w3.org/2001/XMLSchema#string

P698

23736298

http://www.w3.org/2001/XMLSchema#string

P932

3781638

http://www.w3.org/2001/XMLSchema#string